Quetiapine in the treatment of schizophrenia and related disordes

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 2, 2007, Pages 219-235

  Riedel, Michael ^a   Müller, Norbert ^a   Stradding, Martin ^b   Spellmann, Ilja ^a   Severus, Emanuel ^a   Möller, Hans Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antipsychotic; Efficacy; Quetiapine; Schizophrenia; Tolerability

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CIMETIDINE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DROPERIDOL; ERYTHROMYCIN; FLUOXETINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; IMIPRAMINE; LITHIUM SALT; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENYTOIN; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; THIORIDAZINE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

ADD ON THERAPY; AGITATION; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ARTICLE; ASTHENIA; BINDING AFFINITY; BIPOLAR DEPRESSION; BORDERLINE STATE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONDUCT DISORDER; CONSTIPATION; DEMENTIA; DIABETIC KETOACIDOSIS; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; DYSTONIA; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GLUCOSE INTOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; LEUKOPENIA; LOW DRUG DOSE; MANIA; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; MONOTHERAPY; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPPOSITIONAL DEFIANT DISORDER; ORTHOSTATIC HYPOTENSION; PARKINSONISM; POSITIVE SYNDROME; QT PROLONGATION; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SYNCOPE; SYSTEMATIC REVIEW; TACHYCARDIA; TARDIVE DYSKINESIA; THERAPY RESISTANCE; TRANQUILIZING ACTIVITY; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

EID: 34249887085     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2007.3.2.219     Document Type: Article

References (107)

1. Adson DE, Kushner MG, Eiben KM, et al. 2004. Preliminary Experience With Adjunctive Quetiapine In Patients Receiving Selective Serotonin Reuptake Inhibitors. Depr Anxiety, 19:121-6.
2. Allison DB, Mentore JL, Heo M, et al. 1999. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry, 156:1686-96.
3. Andreasen NC, 1982. Negative symptoms in schizophrenia. Arch Gen Psychiatry, 39:784-8.
4. Arvanitis LA, Miller BG; the Seroquel Trial 13 Study Group. 1997. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry, 42:233-46.
5. Atmaca M, Kuloglu M, Tezcan E, et al. 2002. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res, 33:562-5.
6. Bandelow B, Rüther E. 2000. Quetiapin - ein neues atypisches Antipsychotikum. Fundamenta Psychiatrica, 14:127-31.
7. Barnes TRE. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry, 154:672-6.
8. Bednar MM, Harrigan EP, Anziano RJ, et al. 2001. The QT interval. Prog Cardiovasc Dis, 43:1-45.
9. Brecher M, Rak IW, Melvin K, et al. 2000. The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract, 4:287-91.
10. Buckley PF. 2004. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin, 20(9):1357-63.
11. Bellino S, Paradiso E, Bogetto F, 2006. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry, 67:1042-6.
12. Borison RL, Arvanitis LA, Miller BG; the U.S. SEROQUEL Study Group. 1996. ICI 204, 636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol, 16:158-69.
13. Buckley PF, Goldstein JM, Emsley RA. 2004. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schiz Res, 66:143-50.
14. Buckley PF. 2004. Maintenance treatment for schizophrenia with quetiapine. Hum Psychopharmacol Clin Exp, 19:121-4.
15. Calabrese JR, Keck PE, Macfadden W, et al. 2005. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of Bipolar I or II depression. Am J Psychiatry, 162:1351-60.
16. Chengappa KN, Goldstein JM, Greenwood M, et al. 2003. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Therapeutics, 25:530-41.
17. Chouinard G, et al. 1980. Extrapyramidal Symptom Rating Scale. Can J Neurol Sci, 7:233.
18. Chue P, Cheung R. 2006. Minimising the risk of diabetes in patients with schizophrenia and bipolar disorder. Int J of Psychiatr in Clin Pract, 10:105-16.
19. DelBello MP, Schwiers ML, Rosenberg HL, et al. 2002. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry, 41:1216-23.
20. De Nayer A, Windhager E, Irmansyah, et al. on behalf of the SPECTRUM study group, 2003. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psych Clin Pract, 7:59-66.
21. DeVane CL, Nemeroff CB. 2001. Clinical pharmakokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet, 40:509-22.
22. Emsley R, Buckley P, Jones AM, et al. 2003. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol, 17(2):210-5.
23. Emsley R, Turner HJ, Schronen J, et al. 2004. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry, 65:696-701.
24. Ferreira R, Murray J. 1983. Spielberger's State-Trait Anxiety Inventory: Measuring anxiety with and without an audience during performance on a stabilometer. Percept Mot Skills, 57:15-18.
25. Ganesan S, Levy M, Bilsker D, et al. 2005. Effectiveness of quetiapine for the management of aggressive psychosis in the emergency psychiatric setting: a naturalistic uncontrolled trial. Int J Psychiatr Clin Pract, 9:199-203.
26. Ganguli R, Strassnig M, 2006. Are older antipsychotic drugs obsolete? BMJ, 332:1346-1347.
27. 2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol, 11:105-10.
28. Gianfrancesco F, White R, Wang RH, et al. 2003. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol, 23:328-35.
29. Glassman AH, Bigger JT Jr. 2001. Antipsychotic drugs:prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry, 158:1774-82.
30. Goldstein J. 1999. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today, 35:193-210.
31. Good KP, Kiss I, Buiteman C, et al. 2002. Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry, 181(Suppl 43): s45-s49.
32. Guy W, Bonato RR, eds. 1970. Manual for the ECDEU Assessment Battery. 2nd Revised ed. Chevy Chase, Md: National Institute of Mental Health: 12-1-12-6.
33. Guy W, ed. 1976. ECDEU Assessment Manual for Psychopharmacology. Revised ed. Washington DC: US Department of Health, Education and Welfare.
34. Hamilton M. 1960. A rating scale for depression. J Neurol Neursurg Psychiatry, 23:56-62.
35. Hamner MB, Arvanitis LA, Miller BG, et al. 1996. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204, 636). Psychopharmacol Bull, 32:107-10.
36. Harrigan EP, Miceli JJ, Anziano R, Watsky E, et al. 2004. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol, 24:62-9.
37. Jin H, Meyer JM, Jeste DV. 2004. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res, 71:195-212.
38. Jones A, Rak I, Raniwalla J, et al. 2000. Weight changes in patients treated with quetiapine. Presented at the 153rd annual meeting of the American Psychiatric Association. May 13-18; Chicago, Ill.
39. Kapur S, Zipursky R, Jones C, et al. 2000. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry, 57:553-9.
40. Kasper S, Brecher M, Fitton L, et al. 2004. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacol, 19:281-9.
41. Kasper S. 2004. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety, 20:44-7.
42. Koller EA, Weber J, Doraiswamy PM, et al. 2004. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry, 65:857-63.
43. Kay SR, Fiszbein A, Opler LA. 1987. The Positive and Negative Syndrome Scale for schizophrenia. Schizophr Bull, 13:261-76.
44. Larmo I, de Nayer A, Windhager E, et al. 2005. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Human Psychopharmacol Clin Exp, 20:573-581.
45. Leslie DL, Rosenheck RA. 2004. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry, 161:1709-11.
46. Leucht S, Pitschel-Walz G, Abraham D. 1999. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res, 35:51-68.
47. Li KY, Li X, Cheng ZN, et al, 2004. Multiple dose pharmakokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. Acta Pharmacol Sin, 25(3):390-4.
48. Li KY, Li X, Cheng ZN, et al, 2005. Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia. Eur J Clin Pharmacol, 60(11):791-5.
49. Lieberman JA, Perkins DO, 2002. Quetiapine: A 5-Year Update. J Clin Psychiatry, 63, suppl 13.
50. Lieberman JA, Strout TS, McEvoy JP, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353(12):1209-1223.
51. Lin SH, Chang Y, Moody DE, Foltz RL. 2004. A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: Application to a Study of In Vitro Metabolism. J Analyt Toxicol, Vol. 28.
52. McConville BJ, Arvanits LA, Thyrum PT, et al. 2000. Pharmakokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label-trial in adolescents with psychotic disorders. J Clin Psychiatry, 61:252-60.
53. McEvoy JP, Lieberman JA, Stroup TS, et al. 2006. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry, 163:600-10.
54. McConville B, Carrero L, Sweitzer D, et al. 2003. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol, 13:73-80.
55. Meltzer H, Lee M. 2001. Quetiapine is significantly superior to haloperidol and placebo in improving mood in patients with schizophenia. Presented at the 7th World Congress of Biological Psychiatry, Berlin, Germany.
56. Meyer JM, Koro CE. 2004. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res, 70:1-17.
57. Mishara AL, Goldberg TE, 2004. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophenia: opening a closed book. Biol Psychiatry, 55:1013-22.
58. Möller HJ. 1999. Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci, 249(Suppl 4):99-107.
59. Morgante L, Epifanio A, Spina E, et al. 2004. Quetiapine and Clozapine in Parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol, 27:153-6.
60. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. 2004. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord, 18:738-50.
61. Mukherjee S, Decina P, Boccola V, et al. 1996. Diabetes mellitus in schizophrenic patients. Compr Psychiatry, 37:68-73.
62. Mullen J, Jibson MD, Sweitzer D. 2001. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) Study. Clin Therapeutics, 23:1839-54.
63. Nagy J. 2003. Effectiveness of Quetiapine up to 1.600 mg/day: Short-term Results with 14-month Follow-up. Poster presented at the 16th Congress of the European College of Neuropsychopharmacology. September 20-24 2003; Prague, Czech Republic.
64. Nasrallah HA, Tandon R. 2002. Efficacy, Safety, and Tolerability of Quetiapine in Patients With Schizophrenia. J Clin Psychiatry, 63(Suppl 13):12-20.
65. Nemeroff CB, Kinkead B, Goldstein J. 2002. Quetiapine: preclinical studies, pharmakokinetics, drug interactions, and dosing. J Clin Psychiatry, 63(Suppl 13):5-11.
66. Overall JE, Gorham DR. 1962. The Brief Psychiatric Rating Scale. Psychol Rep, 10:799-812.
67. Perkins DO. 1999. Adherence to antipsychotic medications. J Clin Psychiatry, 60(Suppl 21):25-30.
68. Peuskens J, Link CG. 1997. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand, 96:265-73.
69. Potkin S, Thyrum P, Bera R, et al. 1997. Pharmakokinetics and safety of lithium coadministered with Seroquel (quetiapine) [abstract]. Schizophr Res, 24:199.
70. Potkin SG, Thyrum PT, Alva G, et al. 2002a. The safety and pharmakokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol, 22:121-30.
71. Potkin SG, Thyrum PT, Alva G, et al. 2002b. Effect of fluoxetine and imipramine on the pharmakokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol, 22:174-82.
72. Potkin SG, Gharabawi GM, Greenspan AJ, et al. 2006. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencieng an acute exacerbation requring hospitalization. Schizophr Res, 85:254-65.
73. Pardon SE, Malla A, Labelle A, et al. 2001. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci, 26:137-49.
74. Riedel M, Muller N, Strassnig M, et al. 2005. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci, 255:432-7.
75. Riedel M, Spellmann I, Strassnig M, et al. 2007a. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. In press.
76. Riedel M, Spellmann I, Engel RR, et al. 2007b.Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci. In press.
77. Richelson E, Souder T. 2000. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci, 68:29-39.
78. Sacchetti E, Valsecchi P, Regini C, et al. 2004. Comparison of quetiapine ("Seroquel"), olanzapine and risperidone in a randomized study in patients with schizophrenia. Presented at the XXIV Collegium Internationale Neuro-Psychopharmacologicum. June 20-24 2004; Paris, France.
79. Sachs G, Chengappa KNR, Suppes T, et al. 2004. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord, 6:213-23.
80. Sax KW, Strakowski SM, Keck PE Jr. 1998. Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res, 33:151-5.
81. Schneider L, Tariot P, Mintzer J, et al. 2004. Cerebrovascular adverse events and quetiapine: a pooled analysis in elderly patients with dementia. Presented at the 9th International Conference on Alzheimer's Disease and Related Disorders. July 17-22 2004; Philadelphia, PA, USA.
82. Schulz S, Thomson R, Brecher M. 2003. The efficacy of quetiapine vs. haloperidol and placebo: a meta-analytic study of efficacy. Schizophr Res, 62:1-12.
83. Shaw JA, Lewis JE, Pascal S, et al. 2001. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol, 11:415-24.
84. Simpson GN, Angus JWS. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand, 212(Suppl 44):11-9.
85. Small JG, Hirsch SR, Arvanitis LA, et al. 1997. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry, 54:549-57.
86. Small JG, Kellams JJ, Kolar, MC., 2002. Relationship between quetiapine dose and efficacy. Presented at the 15th European College of Neuropsychopharmacology Congress. October 5-9 2002; Barcelona, Spain.
87. Srisurapanont M, Maneeton B, Maneeton N. 2004. Quetiapine for schizophrenia. Cochr Datab Syst Rev, 2:CD000967.
88. Stahl S. 2005. Essential psychopharmacology. Neuroscientific basis and practical applications. 2nd ed. Cambridge University Press. p 415-24.
89. Stevens JR, Kyrmissis PI, Baker AJL. 2005. Elevated Prolactin Levels in Male Youths Treated with Risperidone an Quetiapine. J Child Adolesc Psychopharmacol, 15:893-900.
90. Strakowski SM, Keck PE Jr, Wong YW, et al. 2002. The effect of multiple dose of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders. J Clin Psychopharmacol, 22:201-5.
91. Strassnig M, Brar JS, Ganguli R. 2003. Quality of life and body weight in community-dwelling schizophrenic patient. Schizophr Res, 62:73-6.
92. Strassnig M, Brar JS, Ganguli R, 2005. Self-reported body weight perception and dieting practices in community-dwelling schizophrenia patients. Schizophr Res, 75:425-32.
93. Stroup TS, Lieberman JA, McEvoy JP, et al. 2006. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry, 163:611-22.
94. Sussman N. 2001. Review of atypical antipsychotics and weight gain. J Clin Psychiatry, 62(Suppl 23):5-12.
95. Tandon R. 2004. Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum Psychopharmacol, 19:559-63.
96. Tandon R, Jibson MD. 2005. Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Intern J Psychiatr in Clin Pract, 9:204-12.
97. Tarazi FI, Zhang K, Baldessarini RJ. 2001. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther, 297:711-17.
98. Tariot PN, Salzman C, Yeung PP, et al. 2000. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Therapeutics, 22:1068-84.
99. Thyrum PT, Wong YW, Yeh C. 2000. Single-dose pharmakokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry, 24:521-33.
100. Reilly JG, Ayis SA, Ferrier IN, et al. 2000. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet, 355:1048-52.
101. Velligan DI, Prihoda TJ, Sui D, et al. 2003. Effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry, 64:524-31.
102. Velligan DI, Newcomer J, Pultz J, et al. 2002. Does cognitive function improbe with quetiapine in comparison to haloperidol? Schizophr Res, 53:239-48.
103. Vieta E, Mullen J, Brecher M, et al. 2005. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin, 21:923-34.
104. Vieweg WVR, 2003. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Comp J Clin Psychiatry, 5:205-15.
105. Young RC, Biggs JT, Ziegler VE, et al. 1978. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry, 133:429-35.
106. Zhong K, Tariot P, Minkwitz MC, et al. 2004. Quetiapine for the treatment of agitation in elderly institutionalized patients with dementia: a randomized, double-blind trial. Presented at the 9th International Conference on Alzheimer's Disease and Related Disorders. July 17-22 2004; Philadelphia, PA, USA.
107. Zhong KX, Sweitzer DE, Hamer RM, et al. 2006. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry, 67:1093-103.